Fig 1.
Flowchart of inclusion/exclusion criteria for the study population.
Abbreviations: RA rheumatoid arthritis; b/tsDMARD biologic or targeted synthetic disease-modifying anti-rheumatic drug; SCQM Swiss Clinical Quality Management in Rheumatic Diseases.
Table 1.
Patient characteristics.
Fig 2.
Logistic regression assessing the effect of sex/gender on the study outcomes, with 12-month maximum follow-up.
Abbreviations: n number; OR odds ratio; ORadj odds ratio adjusted for age and seropositivity; DAS28 Disease Activity Score 28; rem/LDA remission or low disease activity; RADAI-5 Rheumatoid Arthritis Disease Activity Index-5.
Table 2.
Logistic regression assessing the effect of sex/gender on the study outcomes, with maximum follow-up of 9- and 15-months.
Table 3.
Summary findings from the mediation analyses (steps I and II), and findings from the main analysis for reference.